|01 April 2021||
Executed a research collaboration agreement with JCR Pharmaceuticals.
|15 Sept. 2020||
Introduced in Startup Guide Japan.
|12 Sept. 2020||
Expanded our drug-resistant mRNA series: now puromycinR, blastcidinR, hygromycinR mRNA are available.
|08 Sept. 2020||
Selected for the Strategic Core Technology Advancement Program (Supporting Industry Program)
|05 Nov. 2019||
Successfully obtained Series A Funding.
|30 Jul. 2019||
Received the hosei-monodukuri' grant-in aid.
|28 Jun. 2019||
Commenced sales of RNA Switch reagents for cell purification.
|19 Dec. 2018||
Received the 'Kigyounomori/Sangakunomori' promotion for business grant from Kyotosaangyo 21.
|09 Nov. 2018||
Successfully obtained seed round funding.
|27 Sep. 2018||
Received the research & development grant from Mitsubishi UFJ Technology Development Foundation.
We commit ourselves to contribute to the fields of regerative medicine and drug discovery through exloration of novel funtions of microRNAs.
What is RNA Switch technology？ RNA Switch for cardiomyocyte purification: CM purifier Custom synthesis of RNA Switch RNA Switch Library and HTP Screening platform for disease-related microRNAs
COMPANY & TEAM